Obligation Abbott 6.15% ( US002819AC45 ) en USD

Société émettrice Abbott
Prix sur le marché refresh price now   110.18 %  ▲ 
Pays  Etats-unis
Code ISIN  US002819AC45 ( en USD )
Coupon 6.15% par an ( paiement semestriel )
Echéance 29/11/2037



Prospectus brochure de l'obligation Abbott US002819AC45 en USD 6.15%, échéance 29/11/2037


Montant Minimal 1 000 USD
Montant de l'émission 1 000 000 000 USD
Cusip 002819AC4
Notation Standard & Poor's ( S&P ) A ( Qualité moyenne supérieure )
Notation Moody's A3 ( Qualité moyenne supérieure )
Prochain Coupon 30/05/2024 ( Dans 9 jours )
Description détaillée L'Obligation émise par Abbott ( Etats-unis ) , en USD, avec le code ISIN US002819AC45, paye un coupon de 6.15% par an.
Le paiement des coupons est semestriel et la maturité de l'Obligation est le 29/11/2037

L'Obligation émise par Abbott ( Etats-unis ) , en USD, avec le code ISIN US002819AC45, a été notée A3 ( Qualité moyenne supérieure ) par l'agence de notation Moody's.

L'Obligation émise par Abbott ( Etats-unis ) , en USD, avec le code ISIN US002819AC45, a été notée A ( Qualité moyenne supérieure ) par l'agence de notation Standard & Poor's ( S&P ).







file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
424B5 1 a2180794z424b5.htm 424B5
QuickLinks -- Click here to rapidly navigate through this document
CALCULATION OF REGISTRATION FEE
Maximum
Maximum
Amount to be
Offering
Amount of
Title of Each Class of Securities to be Registered


Aggregate

Registered
Price Per
Registration Fee
Offering Price
Unit
5.150% Notes due 2012
$ 1,000,000,000
99.961% $
999,610,000 $
30,700
5.600% Notes due 2017
$ 1,500,000,000
99.699% $ 1,495,485,000 $
46,050
6.150% Notes due 2037
$ 1,000,000,000
99.600% $
996,000,000 $
30,700
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-132104
Prospectus Supplement
(To Prospectus dated February 28, 2006)
$3,500,000,000
Abbott
Abbott Laboratories
$1,000,000,000 5.150% Notes due 2012
$1,500,000,000 5.600% Notes due 2017
$1,000,000,000 6.150% Notes due 2037
We are offering $1,000,000,000 aggregate principal amount of 5.150% Notes due 2012 (the "2012 Notes"),
$1,500,000,000 aggregate principal amount of 5.600% Notes due 2017 (the "2017 Notes") and $1,000,000,000
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (1 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
aggregate principal amount of 6.150% Notes due 2037 (the "2037 Notes" and, together with the 2012 Notes
and the 2017 Notes, the "notes"). Interest on the notes will be paid semi-annually in arrears on May 30 and
November 30 of each year, beginning on May 30, 2008. The 2012 Notes will mature on November 30, 2012,
the 2017 Notes will mature on November 30, 2017 and the 2037 Notes will mature on November 30, 2037. We
may redeem some or all of the notes at any time and from time to time at our option. The redemption prices
are discussed under the heading "Description of Notes--Redemption of the Notes."
The notes will be our general unsecured senior obligations and will rank equally with all of our other
unsecured senior indebtedness from time to time outstanding.
Investing in the notes involves risks. See "Risk Factors" beginning on page S-2 of this prospectus supplement.
Price to
Underwriting
Proceeds, before




Public(1)
Discounts
expenses, to Us
Per 2012 Note

99.961%

0.350%

99.611%
Total

$999,610,000

$3,500,000

$996,110,000
Per 2017 Note

99.699%

0.450%

99.249%
Total

$1,495,485,000

$6,750,000

$1,488,735,000
Per 2037 Note

99.600%

0.875%

98.725%
Total

$996,000,000

$8,750,000

$987,250,000
(1)
Plus accrued interest from November 9, 2007, if settlement occurs after that date.
Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is
truthful or complete. Any representation to the contrary is a criminal offense.
The notes will not be listed on any national securities exchange. Currently, there is no public market for the
notes.
The underwriters expect to deliver the notes in book-entry form only through the facilities of The Depository
Trust Company for the accounts of its participants, including Clearstream Banking, societe anonyme, and
Euroclear Bank S.A./N.V., as operator of the Euroclear System, against payment in New York, New York on
November 9, 2007.
Joint Book-Running Managers
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (2 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
Morgan Stanley

BNP PARIBAS

Citi

Wachovia Securities
Senior Co-Managers
ABN AMRO Incorporated

Banc of America Securities
JPMorgan
LLC
Co-Managers
Banca IMI
BMO Capital Markets
Deutsche Bank Securities
Goldman, Sachs & Co.
Mitsubishi UFJ Securities
SOCIETE GENERALE
THE WILLIAMS CAPITAL GROUP, L.P.
The date of this prospectus supplement is November 6, 2007.
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (3 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
TABLE OF CONTENTS
Prospectus Supplement
Page


About this Prospectus Supplement

S-ii
Abbott Laboratories

S-1
Risk Factors

S-2
Cautionary Statement Regarding Forward-Looking Statements

S-4
Use of Proceeds

S-5
Ratio of Earnings to Fixed Charges

S-5
Capitalization

S-6
Description of Notes

S-7
Material U.S. Federal Income Tax Considerations

S-12
Underwriting

S-16
Legal Opinions

S-19
Experts

S-19
Prospectus
Page


About this Prospectus

2
Abbott Laboratories

2
Use of Proceeds

2
Description of Debt Securities

3
Legal Opinions

11
Experts

12
Where You Can Find More Information

12
S-i
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (4 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
ABOUT THIS PROSPECTUS SUPPLEMENT
This document is in two parts. The first part is this prospectus supplement, which describes the specific
terms of this offering. The second part, the accompanying prospectus, gives more general information, some of
which may not apply to this offering. You should read the entire prospectus supplement, as well as the
accompanying prospectus and the documents incorporated by reference that are described under "Where You
Can Find More Information" in the accompanying prospectus.
You should rely only on the information contained or incorporated by reference in this prospectus
supplement and the accompanying prospectus. We have not, and the underwriters have not, authorized any other
person to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell these
securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information
appearing in this prospectus supplement, the accompanying prospectus, and the documents incorporated by
reference is accurate only as of the respective dates of those documents in which the information is contained.
Our business, financial condition, results of operations, and prospects may have changed since those dates.
References to "Abbott," "we," "us," and "our" in this prospectus supplement and the accompanying
prospectus are to Abbott Laboratories, or Abbott Laboratories and its consolidated subsidiaries, as the context
requires.
S-ii
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (5 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
ABBOTT LABORATORIES
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's principal business is the
discovery, development, manufacture, and sale of a broad line of health care products. Abbott's products are
generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices
and government agencies throughout the world.
Abbott's reportable segments are as follows:
Pharmaceutical Products--Worldwide sales of a broad line of pharmaceuticals. For segment reporting
purposes, two pharmaceutical divisions are aggregated and reported as the Pharmaceutical Products segment.
Nutritional Products--Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products--Worldwide sales of diagnostic systems and tests for blood banks, hospitals,
commercial laboratories and alternate-care testing sites. For segment reporting purposes, three diagnostic
divisions are aggregated and reported as the Diagnostic Products segment.
Vascular Products--Worldwide sales of coronary, endovascular and vessel closure products.
Under an agreement between Abbott and Takeda Pharmaceutical Company, Limited of Japan ("Takeda"),
TAP Pharmaceutical Products Inc. (owned 50 percent by Abbott and 50 percent by an affiliate of Takeda),
together with its subsidiary, TAP Pharmaceuticals Inc. ("TAP"), develops and markets pharmaceutical products
primarily for the United States and Canada. TAP's products are generally sold directly to physicians, retailers,
wholesalers, health care facilities, and government agencies.
S-1
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (6 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
RISK FACTORS
Before you decide to invest in the notes, you should consider the factors set forth below as well as the risk
factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2006, which is
incorporated by reference into this prospectus supplement and the accompanying prospectus. See "Where You
Can Find More Information" in the accompanying prospectus.
A public trading market for the notes may not develop.
We have not applied and do not intend to apply for listing of the notes on any securities exchange or any
automated quotation system. As a result, a market for the notes may not develop or, if one does develop, it may
not be sustained. If an active market for the notes fails to develop or cannot be sustained, the trading price and
liquidity of the notes could be adversely affected.
The market price of the notes may be volatile.
The market price of the notes will depend on many factors that may vary over time and some of which are
beyond our control, including:
·
our financial performance;
·
the amount of indebtedness we and our subsidiaries have outstanding;
·
market interest rates;
·
the market for similar securities;
·
competition; and
·
general economic conditions.
As a result of these factors, you may only be able to sell your notes at prices below those you believe to be
appropriate, including prices below the price you paid for them.
An increase in interest rates could result in a decrease in the relative value of the notes.
In general, as market interest rates rise, notes bearing interest at a fixed rate generally decline in value
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (7 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
because the premium, if any, over market interest rates will decline. Consequently, if you purchase these notes
and market interest rates increase, the market value of your notes may decline. We cannot predict the future level
of market interest rates.
Ratings of each series of notes may not reflect all risks of an investment in the notes.
We expect that the notes will be rated by at least one nationally recognized statistical rating organization.
The ratings of the notes will primarily reflect our financial strength and will change in accordance with the rating
of our financial strength. Any rating is not a recommendation to purchase, sell, or hold the notes. These ratings
do not correspond to market price or suitability for a particular investor. In addition, ratings at any time may be
lowered or withdrawn in their entirety.
The notes do not restrict our ability to incur additional debt or prohibit us from taking other action that could
negatively impact holders of the notes.
We are not restricted under the terms of the indenture governing the notes or the notes from incurring
additional indebtedness. The terms of the indenture limit our ability to secure additional debt without also
securing the notes and to enter into sale and leaseback transactions. However, these limitations are subject to
numerous exceptions. See "Description of Debt Securities--Certain Covenants of the Company" in the
accompanying prospectus. In addition, the notes do not require us to achieve or
S-2
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (8 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
maintain any minimum financial results relating to our financial position or results of operations. Our ability to
recapitalize, incur additional debt, secure existing or future debt, or take a number of other actions that are not
limited by the terms of the indenture and the notes, including repurchasing indebtedness or common shares or
preferred shares, if any, or paying dividends, could have the effect of diminishing our ability to make payments
on the notes when due.
Our financial performance and other factors could adversely impact our ability to make payments on the
notes.
Our ability to make scheduled payments with respect to our indebtedness, including the notes, will depend
on our financial and operating performance, which, in turn, are subject to prevailing economic conditions and to
financial, business, and other factors beyond our control.
The notes will be unsecured and subordinated to our secured debt, which makes the claims of holders of
secured debt senior to the claims of holders of the notes.
The notes will be unsecured. As of September 30, 2007, we did not have any significant secured debt
outstanding. The holders of any secured debt that we may have may foreclose on our assets securing our debt,
reducing the cash flow from the foreclosed property available for payment of unsecured debt. The holders of any
secured debt that we may have also would have priority over unsecured creditors in the event of our liquidation.
In the event of our bankruptcy, liquidation, or similar proceeding, the holders of secured debt that we may have
would be entitled to proceed against their collateral, and that collateral will not be available for payment of
unsecured debt, including the notes. As a result, the notes will be effectively subordinated to any secured debt
that we may have.
The notes are effectively subordinated to the liabilities of our subsidiaries, which may reduce our ability to use
the assets of our subsidiaries to make payments on the notes.
The notes are not guaranteed by our subsidiaries and therefore the notes will be effectively subordinated to
all existing and future indebtedness and other liabilities of our subsidiaries. In the event of a bankruptcy,
liquidation, or similar proceeding of a subsidiary, following payment by the subsidiary of its liabilities, the
subsidiary may not have sufficient assets to make payments to us. As of September 30, 2007, our subsidiaries had
approximately $1.2 billion of outstanding indebtedness (excluding intercompany debt and liabilities and accounts
payable incurred in the ordinary course of business).
S-3
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15...Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (9 of 62)11/14/2007 11:37:54 AM


file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.15% Nts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement and the accompanying prospectus and the documents incorporated by reference
include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking
statements are based on management's current expectations, estimates, and projections. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "forecasts," variations of these words, and
similar expressions are intended to identify these forward-looking statements. Certain factors, including but not
limited to those identified under the heading "Risk Factors" in this prospectus supplement, as well as those in
Item 1A, "Risk Factors" to our Annual Report on Form 10-K for the year ended December 31, 2006, which are
incorporated by reference into this prospectus supplement and the accompanying prospectus, may cause actual
results to differ materially from current expectations, estimates, projections, and forecasts and from past results.
You are cautioned not to place undue reliance on such statements, which speak only as of the date made. Abbott
undertakes no obligation to release publicly any revisions to forward-looking statements as the result of
subsequent events or developments.
S-4
file:////23filesrv01/ljs/Tamara/Abbott Laboratories, 5.1...ts due 2012, 5.60% Nts due 2017, 6.150% Nts due 2037.htm (10 of 62)11/14/2007 11:37:54 AM


Document Outline